These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 9858426)

  • 1. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.
    Maetzel A; Bombardier C; Strand V; Tugwell P; Wells G
    J Rheumatol; 1998 Dec; 25(12):2331-8. PubMed ID: 9858426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey.
    Saraux A; Devauchelle-Pensec V; Engerran L; Flipo RM
    J Rheumatol; 2006 Jul; 33(7):1258-65. PubMed ID: 16783865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.
    Criswell LA; Such CL; Yelin EH
    J Rheumatol; 1997 Dec; 24(12):2283-90. PubMed ID: 9415629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Canadian survey of current methotrexate prescribing practices in rheumatoid arthritis.
    Collins D; Bellamy N; Campbell J
    J Rheumatol; 1994 Jul; 21(7):1220-3. PubMed ID: 7966061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis.
    Galindo-Rodriguez G; Avina-Zubieta JA; Fitzgerald A; LeClerq SA; Russell AS; Suarez-Almazor ME
    J Rheumatol; 1997 Apr; 24(4):633-8. PubMed ID: 9101493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
    Zink A; Listing J; Ziemer S; Zeidler H;
    J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.
    Erkan D; Yazici Y; Harrison MJ; Paget SA
    Arthritis Rheum; 2002 Jun; 47(3):285-90. PubMed ID: 12115159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.
    Chakravarty EF; Sanchez-Yamamoto D; Bush TM
    J Rheumatol; 2003 Feb; 30(2):241-6. PubMed ID: 12563675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pregnant and non-pregnant rheumatic patients: a survey among Dutch rheumatologists.
    Vroom F; van de Laar MA; van Roon EN; Brouwers JR; de Jong-van den Berg LT
    J Clin Pharm Ther; 2008 Feb; 33(1):39-44. PubMed ID: 18211615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American College of Rheumatology quality indicators for rheumatoid arthritis: benchmarking, variability, and opportunities to improve quality of care using the electronic health record.
    Adhikesavan LG; Newman ED; Diehl MP; Wood GC; Bili A
    Arthritis Rheum; 2008 Dec; 59(12):1705-12. PubMed ID: 19035412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis?
    Criswell LA; Henke CJ
    J Rheumatol; 1995 May; 22(5):829-35. PubMed ID: 8587068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness.
    Suarez-Almazor ME; Soskolne CL; Saunders LD; Russell AS
    J Rheumatol; 1995 May; 22(5):836-43. PubMed ID: 8587069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events.
    Yazici Y; Erkan D; Paget SA
    Arthritis Rheum; 2003 Oct; 48(10):2769-72. PubMed ID: 14558081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.